ATE316792T1 - Stimulierung wirtseigener abwehrmechanismen gegen krebs - Google Patents

Stimulierung wirtseigener abwehrmechanismen gegen krebs

Info

Publication number
ATE316792T1
ATE316792T1 AT97919564T AT97919564T ATE316792T1 AT E316792 T1 ATE316792 T1 AT E316792T1 AT 97919564 T AT97919564 T AT 97919564T AT 97919564 T AT97919564 T AT 97919564T AT E316792 T1 ATE316792 T1 AT E316792T1
Authority
AT
Austria
Prior art keywords
defense mechanisms
stimulation
host
against cancer
mechanisms against
Prior art date
Application number
AT97919564T
Other languages
English (en)
Inventor
Michael Gerard Tovey
Original Assignee
Pharma Pacific Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9765A external-priority patent/AUPN976596A0/en
Priority claimed from AUPO3959A external-priority patent/AUPO395996A0/en
Priority claimed from AUPO4387A external-priority patent/AUPO438796A0/en
Application filed by Pharma Pacific Pty Ltd filed Critical Pharma Pacific Pty Ltd
Application granted granted Critical
Publication of ATE316792T1 publication Critical patent/ATE316792T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97919564T 1996-05-09 1997-05-05 Stimulierung wirtseigener abwehrmechanismen gegen krebs ATE316792T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPN9765A AUPN976596A0 (en) 1996-05-09 1996-05-09 Stimulation of host defence mechanisms
AUPO3959A AUPO395996A0 (en) 1996-12-03 1996-12-03 Stimulation of host defence mechanisms
AUPO4387A AUPO438796A0 (en) 1996-12-24 1996-12-24 Method of treatment
US08/853,292 US6361769B1 (en) 1996-05-09 1997-05-09 Stimulation of host defense mechanisms against viral challenges

Publications (1)

Publication Number Publication Date
ATE316792T1 true ATE316792T1 (de) 2006-02-15

Family

ID=27424412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97919564T ATE316792T1 (de) 1996-05-09 1997-05-05 Stimulierung wirtseigener abwehrmechanismen gegen krebs

Country Status (15)

Country Link
US (1) US6361769B1 (de)
EP (1) EP0906119B1 (de)
JP (1) JP3806445B2 (de)
CN (1) CN1151841C (de)
AT (1) ATE316792T1 (de)
AU (1) AU724689B2 (de)
BR (1) BR9709068A (de)
CA (1) CA2253971A1 (de)
DE (1) DE69735202T2 (de)
ES (1) ES2260791T3 (de)
ID (1) ID17768A (de)
IL (2) IL126971A0 (de)
NZ (1) NZ332689A (de)
TW (1) TW482676B (de)
WO (1) WO1997041884A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
NZ512628A (en) * 1999-01-08 2004-03-26 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
EP1602378A1 (de) * 1999-12-09 2005-12-07 Chiron Corporation Verfahren zur Verabreichung von Wirkstoffen in das zentrale Nervensystem oder Lymphsystem
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
US6415797B1 (en) * 2000-07-07 2002-07-09 First Circle Medical, Inc. Treatment of human herpesviruses using hyperthermia
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20050031587A1 (en) * 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
DE60324700D1 (de) * 2002-10-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
US20040136917A1 (en) * 2003-01-06 2004-07-15 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
US20050267144A1 (en) * 2003-01-06 2005-12-01 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
CA2548929A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
EP1951288A2 (de) * 2004-06-12 2008-08-06 Pharma Pacific Pty. Ltd. Verfahren zur erhöhung der immunreaktion auf einen impfstoff
EP1870458B1 (de) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2-STRUKTURISOMERE
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101262885B (zh) * 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
JPWO2008007755A1 (ja) * 2006-07-13 2009-12-10 中外製薬株式会社 細胞死誘導剤
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2011512353A (ja) * 2008-02-15 2011-04-21 へミスフェリックス・バイオファーマ,インコーポレーテッド 天然インターフェロン・アルファ種に対する粘膜曝露による、宿主防御機構の遺伝子制御
BRPI1012951A2 (pt) 2009-06-09 2016-07-26 Defyrus Inc "administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
CN102309758B (zh) * 2010-07-02 2013-02-20 北京凯因科技股份有限公司 一种治疗肠道病毒感染引起的疾病的药物组合物
US20130129678A1 (en) 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058192A1 (de) 1980-08-22 1982-08-25 University of Illinois Foundation Abgabe biologisch aktiver komponenten aus interferon isolierten der heterologischen species
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Atll治療用吸入剤
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5215741A (en) 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
JPH06503570A (ja) * 1990-12-14 1994-04-21 シェリング・コーポレーション 肺の悪性腫瘍類を治療するためのアルファーインターフェロンの経口投与
EP0578823B1 (de) 1991-04-08 2002-01-23 Sumitomo Pharmaceuticals Company, Limited Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
US5482706A (en) 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH06298665A (ja) * 1993-04-14 1994-10-25 Toray Ind Inc 抗ウイルス剤
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type

Also Published As

Publication number Publication date
BR9709068A (pt) 2000-01-11
TW482676B (en) 2002-04-11
NZ332689A (en) 2000-07-28
ID17768A (id) 1998-01-29
AU724689B2 (en) 2000-09-28
DE69735202T2 (de) 2006-11-02
WO1997041884A1 (en) 1997-11-13
IL126971A (en) 2007-12-03
EP0906119B1 (de) 2006-02-01
JP3806445B2 (ja) 2006-08-09
US6361769B1 (en) 2002-03-26
DE69735202D1 (de) 2006-04-13
IL126971A0 (en) 1999-09-22
CA2253971A1 (en) 1997-11-13
CN1151841C (zh) 2004-06-02
EP0906119A1 (de) 1999-04-07
JP2000505478A (ja) 2000-05-09
CN1218408A (zh) 1999-06-02
EP0906119A4 (de) 1999-10-20
ES2260791T3 (es) 2006-11-01
AU2399397A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
ATE316792T1 (de) Stimulierung wirtseigener abwehrmechanismen gegen krebs
EP0947222A3 (de) Verfahren zur Aktivierung von photoempfindlichen Mitteln
CA2116559A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
GB9806632D0 (en) Peptide factor
IL105329A0 (en) Halomethylidene derivatives and method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a s-phase or m-phase specific antineoplastic agent
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
NO20003313L (no) Terapeutiske midler
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
IL113280A0 (en) Method of treating auto-immune diseases using type one interferons
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
ATE229981T1 (de) Glykolisierte cytokine
BR9709223A (pt) Estimulação dos mecanismos de defesa do hospedeiro contra tumores.
DE3575671D1 (de) Verwendung von saccharomyces-hefen fuer die herstellung eines arzneimittels gegen amoebiasis.
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
ECSP972109A (es) Estimulacion de los mecanismos de defensa del huesped contra tumores
ECSP972107A (es) Estimulacion de los mecanismos de defensa del huesped contra estimulaciones virales
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
RU97115829A (ru) Способ лечения коклюша у детей
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
CA2080040A1 (en) Methods for preventing mycobacterial infections by administration of rifabutin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906119

Country of ref document: EP

REN Ceased due to non-payment of the annual fee